indazoles has been researched along with 2-oxindole in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Awrey, DE; Ban, F; Beletskaya, I; Cumming, G; Edwards, L; Feher, M; Forrest, B; Hodgson, R; Huang, P; Kiarash, R; Laufer, R; Li, SW; Liu, Y; Luo, X; Madeira, B; Mak, TW; Mao, G; Mason, JM; Nadeem, V; Pan, G; Patel, NK; Pauls, HW; Plotnikova, O; Sampson, PB; Wei, X | 1 |
1 other study(ies) available for indazoles and 2-oxindole
Article | Year |
---|---|
The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor ag
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Survival; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Female; HCT116 Cells; Humans; Indazoles; Indoles; Male; MCF-7 Cells; Mice, Nude; Mice, SCID; Models, Chemical; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2015 |